Civitas Therapeutics, Inc. develops transformative pulmonary delivery therapies. The company was founded by Glenn Batchelder, Richard P. Batycky, Martin I. Freed, Jennifer Fujii, Jeffrey Elton and James L. Wright on June 17, 2009 and is headquartered in Ardsley, NY.

Acusphere is a specialty pharmaceutical company, primarily focused on the development of Imagify™ (perflubutane polymer microspheres) injectible suspension, a cardiovascular drug for the detection of coronary artery disease. Acusphere is in the process of seeking regulatory approval of Imagify in Europe, and negotiating a Special Protocol Assessment with FDA for an additional trial required for U.S. approval. Imagify was created using Acusphere’s proprietary porous microparticle technology, which was also used to create three other drugs which have begun clinical development – AI-525 for acute pain, AI-850 for oncology and AI-128 for asthma. AI-525 and AI-850 were sold to Cephalon in transactions totaling $31 million. AI-128 was developed in collaboration with Elan, who contributed $7.5 million to the program. Acusphere’s technology has the potential to create a wide variety of new drugs by reformulating hydrophobic drugs and creating sustained release formulations of existing drugs.

Engages in priniting activities

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

The Liposome Co., Inc. is a biopharmaceutical company engaged in the discovery, development, manufacturing and marketing of proprietary lipid- and liposome-based pharmaceuticals, primarily for the treatment of cancer and\nother related life-threatening illnesses.

Britannia Pharmaceuticals Ltd. engages in the research and development of pharmaceutical products for the neurology market. It mainly develops products for the treatment of Parkinson��s disease. Its products include APO-go PEN intermittent subcutaneous injection, APO-go continuous infusion, Briotlofex, and Denzapine. The company was founded in 1982 and is headquartered in Reading, the United Kingdom.

Servier Laboratories (doing business as Les Laboratories Servier) is a French private company located in Paris. The firm operates as a pharmaceutical company.\nThe company says this about itself: Servier is a global pharmaceutical group governed by a Foundation. With a strong international presence in 150 countries and a total revenue of 4.7 billion euros in 2020, Servier employs 22,500 people worldwide. Servier is an independent group that invests over 20% of its brand-name revenue in Research and Development every year. To accelerate therapeutic innovation for the benefit of patients, the Group is committed to open and collaborative innovation with academic partners, pharmaceutical groups, and biotech companies. It also integrates the patient's voice at the heart of its activities. A leader in cardiology, the ambition of the Servier Group is to become a recognized and innovative player in oncology. Its growth is based on a sustained commitment to cardiovascular and metabolic diseases, oncology and immuno-inflammatory, and neurodegenerative diseases. To promote access to healthcare for all, the Servier Group also offers a range of quality generic drugs covering most pathologies.

Manufactures pharmaceuticals

Otsuka Holdings operates in pharmaceuticals, nutraceuticals, and consumer products. The business activity of the company includes providing healthcare solutions in the areas of the nervous system, oncology, cardiovascular system, respiratory system, infectious disease, and others. The company engages in the research and development of functional foods and beverages, such as electrolyte drinks, nutritional foods, soy snacks, and dietary foods.

A. Nattermann & Cie. GmbH engages in the production of over-the-counter and consumer health care drugs. Its products are sold to distribution firms of the Sanofi group. The company is headquartered in Cologne, Germany.

Bracco International BV wholesales and distributes pharmaceutical products. It engages in the promotion and marketing of products manufactured by Bracco SpA across the world. The company was founded in 1991 and is headquartered in Amsterdam, the Netherlands.

FUJIFILM Wako Pure Chemical Corp. produces and wholesales clinical diagnostic reagents, electronic materials, and chemical products. The firm offers product information, laboratory chemicals, specialty chemicals, clinical diagnostic reagents and equipment. The company was founded in 1922 and is headquartered in Osaka, Japan.

Toshiba Corporation (株式会社東芝 Kabushiki-gaisha Tōshiba, English: /təˈʃiːbə, tɒ-, toʊ-/) is a Japanese multinational conglomerate headquartered in Tokyo, Japan. Its diversified products and services include information technology and communications equipment and systems, electronic components and materials, power systems, industrial and social infrastructure systems, consumer electronics, home appliances, medical equipment, office equipment, as well as lighting and logistics.

Acts as an alternative investment manager

Nektar Therapeutics is a biopharmaceutical company with a robust, wholly owned R&D pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

The National Institute of Advanced Industrial Science and Technology (AIST), led by President Chubachi, is a public research institution funded by the Japanese government to a large extent. The present AIST is a rather new research organization established in 2001. However, AIST and its predecessor organizations have been contributing to society through continuous advancement in technologies and support to Japanese industries since 1882. Headquarters of AIST are located in Tsukuba and Tokyo. AIST has over 40 autonomous research units in various innovative research fields, and the units are located at ten research bases and several sites (smaller than research bases) of AIST all over Japan. About 2300 researchers (about 2000 with tenure: about 80 from abroad) and a few thousands of visiting scientists, post-doctoral fellows, and students from home and abroad are working at AIST. About 650 permanent administrative personnel and many temporary staff support research works of AIST.

KT&G is the leading tobacco company in South Korea with annual sales of over $4 billion USD. KT&G was originally a government-owned monopoly but was privatized and today is publicly traded, competing for market share with other international tobacco firms such as Philip Morris International, British American Tobacco, and Japan Tobacco. KT&G's sales volume share was 62% of the Korean market in 2009. KT&G produces popular Korean cigarette brands such as The One, Indigo, Arirang, This, This Plus, Zest, Esse, Raison, and Lo Crux. It has been expanded outside Korea, especially through its superslims brand Esse in Russia and other eastern European markets. KT&G also owns significant subsidiaries such as Korea Ginseng Corporation, Yungjin Pharm (a pharmaceuticals company), and several bio ventures. Its headquarters are in Daejeon.